These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16393906)
1. 6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization. Agrawal V; Paul MK; Mukhopadhyay AK J Liposome Res; 2005; 15(3-4):141-55. PubMed ID: 16393906 [TBL] [Abstract][Full Text] [Related]
2. Enhanced anticancer potency using an acid-responsive ZnO-incorporated liposomal drug-delivery system. Tripathy N; Ahmad R; Ko HA; Khang G; Hahn YB Nanoscale; 2015 Mar; 7(9):4088-96. PubMed ID: 25660501 [TBL] [Abstract][Full Text] [Related]
3. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers. Shao M; Sun SL; Li MH; Li BX; Yu H; Shen ZY; Ren YC; Hao ZF; Chang ND; Peng HS; Yang BF J Liposome Res; 2012 Jun; 22(2):168-76. PubMed ID: 22428938 [TBL] [Abstract][Full Text] [Related]
4. High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach. Taneja D; Namdeo A; Mishra PR; Khopade AJ; Jain NK Drug Dev Ind Pharm; 2000 Dec; 26(12):1315-9. PubMed ID: 11147134 [TBL] [Abstract][Full Text] [Related]
5. The effects of intermolecular interactions on the stability and in vitro drug release of daunorubicin/cytarabine co-loaded liposome. Liu B; Zhang J; Gou J; Zhang Y; He H; Yin T; Zheng Z; Tang X Colloids Surf B Biointerfaces; 2022 Sep; 217():112673. PubMed ID: 35780612 [TBL] [Abstract][Full Text] [Related]
6. The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids. Gallois L; Fiallo M; Laigle A; Priebe W; Garnier-Suillerot A Eur J Biochem; 1996 Nov; 241(3):879-87. PubMed ID: 8944778 [TBL] [Abstract][Full Text] [Related]
7. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. Ying X; Wen H; Lu WL; Du J; Guo J; Tian W; Men Y; Zhang Y; Li RJ; Yang TY; Shang DW; Lou JN; Zhang LR; Zhang Q J Control Release; 2010 Jan; 141(2):183-92. PubMed ID: 19799948 [TBL] [Abstract][Full Text] [Related]
8. [Study on pharmaceutical characterization and pharmacokinetics of daunorubicin long-circulating liposomes in rat]. Zhang H; Qi XR; Zhang Q Yao Xue Xue Bao; 2002 Apr; 37(4):299-303. PubMed ID: 12579828 [TBL] [Abstract][Full Text] [Related]
9. pH dependence of daunorubicin interactions with model DMPC:Cholesterol membranes. Matyszewska D; Brzezińska K; Juhaniewicz J; Bilewicz R Colloids Surf B Biointerfaces; 2015 Oct; 134():295-303. PubMed ID: 26209780 [TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810 [TBL] [Abstract][Full Text] [Related]
11. Daunorubicin and doxorubicin molecular interplay with 2D membrane models. Alves AC; Nunes C; Lima J; Reis S Colloids Surf B Biointerfaces; 2017 Dec; 160():610-618. PubMed ID: 29028609 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of mono- and multi-hydroxyl low toxicity pH-sensitive cationic lipids for drug delivery. Zhao Z; Yao W; Wang N; Liu C; Zhou H; Chen H; Qiao W Eur J Pharm Sci; 2019 May; 133():69-78. PubMed ID: 30914360 [TBL] [Abstract][Full Text] [Related]
13. Study of azathioprine encapsulation into liposomes. Gulati M; Grover M; Singh M; Singh S J Microencapsul; 1998; 15(4):485-94. PubMed ID: 9651870 [TBL] [Abstract][Full Text] [Related]
14. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. Versluis AJ; Rump ET; Rensen PC; van Berkel TJ; Bijsterbosch MK J Pharmacol Exp Ther; 1999 Apr; 289(1):1-7. PubMed ID: 10086980 [TBL] [Abstract][Full Text] [Related]
15. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. Teixeira RS; Valduga CJ; Benvenutti LA; Schreier S; Maranhão RC J Pharm Pharmacol; 2008 Oct; 60(10):1287-95. PubMed ID: 18812021 [TBL] [Abstract][Full Text] [Related]
16. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting: synthesis, characterization, and proof of concept of hepatospecific delivery. Pathak PO; Nagarsenker MS; Barhate CR; Padhye SG; Dhawan VV; Bhattacharyya D; Viswanathan CL; Steiniger F; Fahr A Carbohydr Res; 2015 May; 408():33-43. PubMed ID: 25841057 [TBL] [Abstract][Full Text] [Related]
17. Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu Zhang J; Zhou L; Zhang Y; He H; Yin T; Gou J; Wang Y; Tang X AAPS PharmSciTech; 2020 Nov; 21(8):325. PubMed ID: 33206247 [TBL] [Abstract][Full Text] [Related]
18. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Dicko A; Kwak S; Frazier AA; Mayer LD; Liboiron BD Int J Pharm; 2010 May; 391(1-2):248-59. PubMed ID: 20156541 [TBL] [Abstract][Full Text] [Related]